Which peptides WADA bans in sport
Regulatory fact: WADA 2026 Prohibited List and the 2027 list. 88 peptides. Last checked .
| Peptide | WADA 2026 status | What the list says | First named |
|---|---|---|---|
| BPC-157 | Prohibited, namedS0 | Named as an example of a non-approved substance. A Specified Substance. | 2022 list |
| TB-500 | Prohibited, namedS2.3 | "Thymosin-ß4 and its derivatives e.g. TB-500." A non-Specified Substance. | On the 2021 list or earlier |
| CJC-1295 | Prohibited, namedS2.2.4 | Named as a GHRH analogue, next to CJC-1293. | On the 2021 list or earlier |
| Sermorelin | Prohibited, namedS2.2.4 | Named as a GHRH analogue. | On the 2021 list or earlier |
| Tesamorelin | Prohibited, namedS2.2.4 | Named as a GHRH analogue. Banned even though Egrifta is FDA-approved. | On the 2021 list or earlier |
| Ipamorelin | Prohibited, namedS2.2.4 | Named as a growth hormone secretagogue. | On the 2021 list or earlier |
| MK-677 (ibutamoren) | Prohibited, namedS2.2.4 | Named as "ibutamoren (MK-677)", a growth hormone secretagogue. Not a peptide, but listed with them. | 2024 list |
| GHRP-2 | Prohibited, namedS2.2.4 | Named as "GHRP-2 (pralmorelin)", a GH-releasing peptide. | On the 2021 list or earlier |
| GHRP-6 | Prohibited, namedS2.2.4 | Named as a GH-releasing peptide. | On the 2021 list or earlier |
| Hexarelin | Prohibited, namedS2.2.4 | Named as "examorelin (hexarelin)", a GH-releasing peptide. | On the 2021 list or earlier |
| AOD-9604 | Prohibited, namedS2.2.3 | Named as a growth hormone fragment. | On the 2021 list or earlier |
| HGH Fragment 176-191 | Prohibited, namedS2.2.3 | Named as "hGH 176-191", a growth hormone fragment. | On the 2021 list or earlier |
| IGF-1 LR3 | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." LR3 is an IGF-1 analogue. | On the 2021 list or earlier |
| PEG-MGF | Prohibited, namedS2.3 | "Mechano growth factors (MGFs)." | On the 2021 list or earlier |
| MOTS-c | Prohibited, namedS4.4.1 | Named as an activator of AMP-activated protein kinase (AMPK), a metabolic modulator. | 2025 list |
| Follistatin-344 | Prohibited, namedS4.3 | Named under myostatin inhibitors: "Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)." Gene therapy delivery is separately prohibited under M3.1. | On the 2021 list or earlier |
| IGF-1 DES | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." Des(1-3)IGF-I is an IGF-1 analogue, and anti-doping labs have validated blood tests for it. | On the 2021 list or earlier |
| Thymosin Beta-4 | Prohibited, namedS2.3 | "Thymosin-ß4 and its derivatives e.g. TB-500." The full-length protein is the named substance; TB-500 is listed as one of its derivatives. A non-Specified Substance. | On the 2021 list or earlier |
| Somatropin (HGH) | Prohibited, namedS2.2.3 | "Growth hormone (GH), its analogues and fragments." The weekly analogues lonapegsomatropin, somapacitan and somatrogon are named as examples. A non-Specified Substance. Banned even though every product is FDA-approved. | On the 2021 list or earlier |
| Mecasermin (Increlex) | Prohibited, namedS2.3 | "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues." A non-Specified Substance. Banned even though Increlex is FDA-approved. | On the 2021 list or earlier |
| Desmopressin | Prohibited, namedS5 | Named under diuretics and masking agents, prohibited in and out of competition. A Specified Substance. | On the 2021 list or earlier |
| hCG | Prohibited in malesS2.2.1 | "Chorionic gonadotrophin (CG)" under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Kisspeptin-10 | Prohibited in malesS2.2.1 | "Kisspeptin and its agonist analogues" under testosterone-stimulating peptides in males. | 2024 list |
| Gonadorelin | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues" under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Leuprolide (leuprorelin) | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues", naming leuprorelin, under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| Triptorelin | Prohibited in malesS2.2.1 | "Gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues", naming triptorelin, under testosterone-stimulating peptides in males. | On the 2021 list or earlier |
| ARA-290 | Prohibited, by classS2.1.5 | Not named. S2.1.5 bans innate repair receptor agonists, the receptor ARA-290 was designed to act on. No approval anywhere, so S0 would also apply. | Not named |
| Retatrutide | Prohibited under S0S0 | Not named. A drug still in clinical trials, which S0 lists as an example of what it covers. | Not named |
| Cagrilintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Survodutide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Eloralintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| SLU-PP-332 | Prohibited under S0S0 | Not named on the 2026 list. No approval anywhere, so S0 covers it.2027: Named under S4.4.1 from January 1, 2027. | Not named |
| Melanotan-2 | Prohibited under S0S0 | Not named. Never approved by any regulator. | Not named |
| Epitalon | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| KPV | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| LL-37 | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| GHK-Cu | Prohibited under S0S0 | Not named. Injectable research product has no drug approval anywhere. The list does not mention cosmetics. | Not named |
| AHK-Cu | Prohibited under S0S0 | Not named. No drug application has ever been filed for it. | Not named |
| Dihexa | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| FOXO4-DRI | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| P21 (P021) | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| PE-22-28 | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| Pinealon | Prohibited under S0S0 | Not named. No approved product anywhere. | Not named |
| Thymulin | Prohibited under S0S0 | Not named. The synthetic form was tested in the 1980s and never approved. | Not named |
| 5-Amino-1MQ | Prohibited under S0S0 | Not named. Not a peptide, and not approved anywhere. | Not named |
| CagriSema (cagrilintide + semaglutide) | Prohibited under S0S0 | Not named. Its cagrilintide component has no approval anywhere, so S0 covers the combination. Semaglutide alone is not banned. | Not named |
| Amycretin (zenagamtide) | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Petrelintide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Pemvidutide | Prohibited under S0S0 | Not named. A drug still in clinical development, with no approval anywhere. | Not named |
| Humanin | Prohibited under S0S0 | Not named. A research peptide with no approval by any regulator for human therapeutic use, which is what S0 covers. | Not named |
| Larazotide | Prohibited under S0S0 | Not named. Never approved anywhere, and its phase 3 development was discontinued in 2022. S0 explicitly covers drugs under clinical development or discontinued. | Not named |
| Semaglutide | Allowed, monitored | Not on the list. In the 2026 Monitoring Program, which tracks use without banning it.2027: Still not banned; still monitored in 2027. | Not named |
| Tirzepatide | Allowed, monitored | Not on the list. In the 2026 Monitoring Program, which tracks use without banning it.2027: Still not banned; still monitored in 2027. | Not named |
| Mazdutide | Not named, approved | Not named. Approved in China in June 2025, and S0 covers only drugs with no approval anywhere. | Not named |
| PT-141 (bremelanotide) | Not named, approved | Not named. FDA-approved as Vyleesi in 2019. | Not named |
| Oxytocin | Not named, approved | Not named. FDA-approved as Pitocin. | Not named |
| Melanotan-1 (afamelanotide) | Not named, approved | Not named. FDA-approved as Scenesse in 2019. | Not named |
| SS-31 (elamipretide) | Not named, approved | Not named. FDA-approved as Forzinity in September 2025. | Not named |
| Thymosin Alpha-1 | Not named, approved | Not named. Approved as Zadaxin in China and other countries for hepatitis B, though not in the US. | Not named |
| Selank | Not named, approved | Not named. Registered as a medicine in Russia (nasal drops). | Not named |
| Semax | Not named, approved | Not named. Sold in Russia as nasal drops with an official label. | Not named |
| Cerebrolysin | Not named, approved | Not named. Authorized as a medicine in Austria, though not registered with the FDA. | Not named |
| VIP (aviptadil) | Not named, approved | Not named. Aviptadil, with phentolamine, is licensed in the UK as Invicorp (marketing authorisation of April 2015). | Not named |
| DSIP | Not named, approved | Not named. Registered in Russia as Deltaran (LP-016126), which contains DSIP with glycine. Approved nowhere else. | Not named |
| Efpeglenatide | Not named, approved | Not named. Approved in South Korea as Eppe in October 2026, and S0 covers only drugs with no approval anywhere. Not on the Monitoring Program, which lists only semaglutide and tirzepatide among GLP-1 drugs. | Not named |
| Liraglutide | Not named, approved | Not named. FDA-approved as Victoza (2010) and Saxenda (2014). Not in the 2026 Monitoring Program, which lists only semaglutide and tirzepatide markers. | Not named |
| Dulaglutide | Not named, approved | Not named. FDA-approved as Trulicity in 2014. Not in the 2026 Monitoring Program, which lists only semaglutide and tirzepatide markers. | Not named |
| Exenatide | Not named, approved | Not named. FDA-approved since 2005 (Byetta); the brands were discontinued in the US in 2024, but generic exenatide is FDA-approved and sold. | Not named |
| Setmelanotide | Not named, approved | Not named. FDA-approved as Imcivree in 2020 and authorized in the EU in 2021. | Not named |
| Teriparatide | Not named, approved | Not named. FDA-approved as Forteo in 2002, with generic versions since 2023. | Not named |
| Abaloparatide | Not named, approved | Not named. FDA-approved as Tymlos in 2017. | Not named |
| Cetrorelix | Not named, approved | Not named. S2.2.1 covers GnRH and its agonist analogues; cetrorelix is a GnRH antagonist. FDA-approved as Cetrotide in 2000. | Not named |
| Khavinson bioregulators | Check firstS0 for most | Not named. Thymalin and Thymogen are registered medicines in Russia; the synthetic organ peptides (Vilon, Cortagen and others) have no drug approval, so S0 covers them. | Not named |
| SNAP-8 | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| NAD+ | Check firstM2.2 | Not a peptide and not named. Any IV infusion or injection over 100 mL in 12 hours is a prohibited method, which covers many NAD+ drips. | Not named |
| Argireline (acetyl hexapeptide-8) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl (palmitoyl pentapeptide-4) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl 3000 | Check first | Not named. A topical cosmetic blend of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, never developed as a drug. The list does not mention cosmetics. | Not named |
| Matrixyl synthe'6 (palmitoyl tripeptide-38) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| SYN-AKE | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics or acetylcholine receptor blockers. | Not named |
| Leuphasyl (pentapeptide-18) | Check first | Not named. A topical cosmetic enkephalin analog, never developed as a drug. S7 is a closed list of named narcotics and does not include it. | Not named |
| Eyeseryl (acetyl tetrapeptide-5) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Melanostatin (nonapeptide-1) | Check first | Not named. A topical cosmetic ingredient that blocks MC1R, never developed as a drug. The list does not mention cosmetics. | Not named |
| Hexapeptide-9 | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Decorinyl (tripeptide-10 citrulline) | Check first | Not named. A topical cosmetic ingredient, never developed as a drug. The list does not mention cosmetics. | Not named |
| Carnosine | Check first | Not named. A dietary supplement and food compound with no drug approval of its own; a zinc-carnosine chelate (polaprezinc) is an approved ulcer drug in Japan. The list does not mention dietary supplements. | Not named |
| Glutathione | Check firstM2.2 | Not named. Approved as an injectable drug in Japan (Tathion), so S0 does not apply. Any IV infusion or injection over 100 mL in 12 hours is a prohibited method, which covers many glutathione drips. | Not named |
| Pramlintide | Check firstS0 possible | Not named. FDA-approved as Symlin in 2005, but every Symlin strength is now listed as discontinued. S0 covers discontinued drugs with no current approval, so ask your anti-doping organization. | Not named |
No peptide matches.